China-US Event to Focus on China's Crackdown Against Foreign Pharmaceutical Firms

Jul 17, 2013, 09:00 ET from Food and Drug Law Institute

WASHINGTON, July 17, 2013 /PRNewswire-USNewswire/ -- The Chinese government is taking a hard line against pharmaceutical companies that violate anti-bribery laws, as seen by the recent actions taken against multinational firms. But this tough enforcement — in what is projected to be the second largest pharmaceutical market in the world — is not limited to only the drug industry. The Food and Drug Law Institute's China-US Updates in Food and Drug Law conference being held in Beijing on October 15-16 will address recent enforcement actions against pharmaceutical, medical device and food companies both in China and the US, focusing on the Foreign Corrupt Practices Act (FCPA), anti-bribery actions and stricter penalties. Learn more.  

(Logo: http://photos.prnewswire.com/prnh/20121211/DC27524LOGO)

Link: http://www.fdli.org/conferences/conference-pages/fdli-international-conference/overview

Contact: Erin Jones, VP, Marketing, emj@fdli.org, 202-222-0899

SOURCE Food and Drug Law Institute



RELATED LINKS

http://www.fdli.org
http://www.fdli.org